Trial Design

INSIGHTS ON CLINICAL TRIAL DESIGN

How A Small Biotech Partnered With Us To Navigate Trial Complexity With Confidence And Control
Early-phase trials often evolve rapidly. See how a flexible RTSM approach helped a biotech sponsor manage major protocol changes without disrupting study execution.
Why Early Phase Speed Depends On Oncology Expertise
Early phase oncology speed depends on confident, oncology‑specific decisions made upfront. Learn why scientific expertise, realistic planning, and foresight determine whether programs maintain momentum.
Navigating The Challenges Of Large, International Phase III Breast Cancer Trials
In the competitive landscape of breast cancer research, aligning biomarker testing, regulatory pathways, and regional operations from day one creates a path to faster enrollment and stronger outcomes.
What Clinical Trial Decision Makers Are Prioritizing In 2025
In 2025, clinical trial operations are undergoing a transformative shift driven by the need for speed, cost-efficiency, and patient-centered approaches.

Retention Through Intention — Designing Truly Patient-Centric Trials
2/4/2026

High drop-out rates threaten clinical trial integrity. Implementing decentralized solutions and proactive support strategies during protocol design can significantly improve patient enrollment and retention.
Site Networks And Hybrid Solutions
7/22/2025

Learn how community- and patient-centric site networks that have DCT capabilities are able to work with a broad-range of site types.
Strategic Implications Of The Single Phase 3 Approval Paradigm
7/21/2026

As FDA single-trial approvals gain traction, CNS developers need stronger early evidence. Learn how biomarkers, patient selection, and regulatory strategy can accelerate development.
Obesity Clinical Research: Patient Recruitment Challenges
1/15/2026

Obesity trials face enrollment hurdles. Learn how data-driven insights, patient-first strategies, and decentralized models can break barriers, ease burden, and accelerate timelines.
Strategies For Biomarker Development And Early Phase Clinical Studies
5/2/2025

Companion diagnostics (CDx) are crucial for personalized medicine to enable precise patient selection for therapies. Explore biomarker development strategies and early-phase study considerations.

Bringing Endocrine And Metabolic Disease Treatments To Market

Metabolic and endocrine diseases are a rising therapy area focus for clinical research due to the high demand for novel therapies that are challenged with proving safety and efficacy.
Overcome Biosafety Challenges With An Innovative IBC

Simplify biosafety oversight and accelerate study startup with expert guidance that ensures NIH compliance while protecting researchers, communities, and the environment.
Solutions For Patients Across Most Therapeutic Areas And Indications

Struggling with slow recruitment or fragmented sites? Explore how 35 coordinated sites and 3.5M+ patients can streamline trials from startup to close.
Accelerate Approval Of Novel Therapies

Learn how to make critical, data-driven decisions throughout the product development lifecycle and increase new therapies' probability of success.
Why Central IRBs Matter For Efficient Clinical Trials

“Going the extra mile is a big part of our DNA. Personal attention can go a long way in ensuring the success of your next research study.”

Raffaella Hart, MS, CIP
Sr. Vice President, IRB and IBC Services

Fast, reliable IRB review for multisite studies backed by expert oversight and responsive support. With streamlined submissions, frequent meetings, and dedicated client managers, BRANY IRB helps you save time and money while maintaining full regulatory compliance.